NCT06682195招募中2 期
Neoadjuvant Chemotherapy Combined With Toripalimab for Triple-negative Breast Cancer : a Prospective, Single-arm, Multi-center Study (NEOTORCH-BREAST02)
First Affiliated Hospital of Zhejiang University13 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2024年10月9日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 35
- 试验地点
- 13
- 主要终点
- pathologic complete response（PCR）
研究概览
简要总结
This study is a prospective, single arm, multi-center phase II clinical trial. The primary study objective is to evaluate the pathologic complete response（PCR） of Adjuvant treatment of TNBC breast cancer with Toripalimab combined with neoadjuvant chemotherapy, including the incidences and types of adverse events. The secondary study objective is to observe and evaluate the disease-free survival (DFS), Progression-Free-Survival (PFS ),and Objective Response Rate(ORR)
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female patients aged 18-70 years old;
- •ECOG score is 0-1 points;
- •Histologically proven tumors >1cm in diameter (T1c-3; N0-2; M0) invasive breast cancer;
- •All patients had triple negative breast cancer confirmed by histopathology;
- •Pathological examination of PD-L1 expression:
- •The Combined Positive Score (CPS) refers to the percentage of PD-L1 positive cells (including tumor cells, lymphocytes, macrophages) in all tumor cells. Our center detected the PD-L1 antibody site as 22C
- •The functional level of major organs must meet requirements
- •For female patients who have not yet reached menopause or undergone surgical sterilization: during the treatment period and in the study treatment, the final use effective contraceptive methods for at least 6 months after a single administration.
- •Voluntarily join this study, sign an informed consent form, have good compliance, and are willing to cooperate with follow-up.
排除标准
- •Stage IV breast cancer.
- •Inflammatory breast cancer.
- •Previously received anti-tumor treatment or radiation therapy for any malignant tumor, excluding those that have been cured Malignant tumors such as cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma.
- •Simultaneously undergoing anti-tumor treatment in other clinical trials, including but not limited to chemotherapy and endocrine therapy. Treatment, biological therapy, bone improvement drug therapy, or immune checkpoint inhibitor therapy, etc.
- •The patient had undergone major surgical procedures unrelated to breast cancer within 4 weeks before the first administration of the study drug, or the patient has not fully recovered from such surgical procedures.
- •Serious heart disease or discomfort, including but not limited to the following diseases:
- •1) Diagnosed history of heart failure or systolic dysfunction (LVEF less than 50%).2) High risk uncontrolled arrhythmias, such as atrial tachycardia, resting heart rate greater than 100bpm, significant ventricular arrhythmias (such as ventricular tachycardia), or higher-level atrioventricular block (i.e. Mobitz II second or third degree atrioventricular block).3) Angina requiring medication for treatment. 4) Heart valve disease with clinical significance. 5) ECG shows transmural myocardial infarction. 6) Poor control of hypertension (systolic blood pressure greater than 180mmHg and/or diastolic blood pressure greater than 180mmHg after drug treatment) 100mmHg).
- •7. Uncontrolled active infections that require treatment; History of immunodeficiency, including HIV testing positive Sexual, or suffering from other acquired or congenital immunodeficiency diseases, or having a history of organ transplantation.
- •8. Patients with chronic active hepatitis B or active hepatitis C (excluding hepatitis B virus carriers, stable hepatitis B after drug treatment [HBV-DNA test negative or<50IU/ml] and cured hepatitis C patients [HCV RNA test negative]).
- •9. Have received immunotherapy and experienced adverse immune events such as immune related pneumonia and myocarditis, which have been determined by researchers to potentially affect the safety of the experimental medication.
- •10. Individuals with a known history of allergies to the components of this medication regimen.
- •11. Pregnant and lactating female patients, female patients with fertility and positive baseline pregnancy test results, or reproductive age patients who are unwilling to take effective contraceptive measures during the entire trial period and within 6 months after the last study medication.
- •12. Suffering from serious accompanying diseases or other comorbidities that may interfere with the planned treatment, or any other circumstances that the researcher deems unsuitable for the patient to participate in this study.
研究组 & 干预措施
Neoadjuvant chemotherapy combined with Toripalimab
Experimental
1, Neoadjuvant Chemotherapy Phase Combined with Toripalimab
- First Phase of Neoadjuvant Chemotherapy: Epirubicin + Cyclophosphamide + Toripalimab. Administered intravenously: 100 mg/m² Epirubicin + 600 mg/m² Cyclophosphamide + 240 mg Toripalimab, every 3 weeks for a total of 6 weeks.
- Second Phase of Neoadjuvant Chemotherapy: Albumin-bound Paclitaxel + Toripalimab. Administered intravenously: 260 mg/m² Albumin-bound Paclitaxel + 240 mg Toripalimab, every 3 weeks for a total of 6 weeks.
2, Receive Breast Cancer Radical Surgery After 4 Cycles of Neoadjuvant Chemotherapy 3, Postoperative Adjuvant Therapy
- If pathology indicates pCR: Continue immunotherapy, administering 240 mg Toripalimab intravenously every 3 weeks for a total of 1 year.
- If pathology indicates non-PCR: Continue postoperative adjuvant chemotherapy combined with Toripalimab.
4, Perform Gene Testing on Biopsy Tissue Before Treatment, and Collect Blood Samples for ctDNA Testing Before and After Treatment.
干预措施: Neoadjuvant chemotherapy combined with Toripalimab (Drug)
结局指标
主要结局
pathologic complete response（PCR）
时间窗: 2 years
The primary study objective is to evaluate the pathologic complete response（PCR） of Neodjuvant treatment of TNBC breast cancer with Toripalimab combined with neoadjuvant chemotherapy and sequential Toripalimab monoclonal antibody
次要结局
- Objective Response Rate(ORR)(3 years)
- Event-free survival (EFS)(3 years)
- radiologic complete response (rCR)(3 years)
研究者
研究点 (13)
Loading locations...
相似试验
招募中
2 期
Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)HR+/HER2- Breast CancerNCT06611813First Affiliated Hospital of Zhejiang University30
招募中
2 期
Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLCRET Driver MutationBRAF V600 MutationErb-B2 Receptor Tyrosine Kinase Exon 20 MutationMET AmplificationMET Exon 14 Skipping MutationNon-Small Cell Lung CancerNCT05800340Guangdong Provincial People's Hospital30
招募中
不适用
Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal CancerLocally AdvancedHigh-RiskRectal CancerMSSNCT05877573Nanfang Hospital, Southern Medical University53
招募中
2 期
Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive ExpressionCarcinoma, Non-Small-Cell LungNCT06269211Ruijin Hospital29
招募中
1 期
Induction Toripalimab and Chemotherapy in Locally Advanced Cervical CancerInduction ChemotherapyImmunotherapyCervical CancerNCT06093438Tianjin Medical University Cancer Institute and Hospital20